Association Study of Age Acceleration and Cancer RiskInquiry
The true age of a person can be determined by measuring DNA methylation levels, a phenomenon known as age acceleration when there is a discrepancy between the predicted age and the actual age. This can be used as a marker of human aging and has been found to be possibly associated with cancer risk.
As a biological service provider for aging research, CD BioSciences can provide services to investigate the relationship between methylation age acceleration and cancer risk.
Methylation-Based Biological Age and Cancer Risk
Changes in DNA methylation levels with age, and it has been widely studied as a well-known biomarker of aging. A number of DNA methylation age clocks have appeared and been used, and when the age predicted by the methylation clock is greater than the actual age, it is considered to have "age acceleration", which is also called the biological measure of aging.
Research suggests a correlation between aging and cancer as well. Predicted ages obtained by DNA methylation analysis are greater than actual ages, indicating age acceleration, and these phenomena may also be strongly associated with cancer risk. By analyzing the age acceleration of DNA methylation to discover their association with increased cancer risk or shorter survival, it could help to understand specific relationship between the aging process and cancer development, developing DNA methylation as a tool for predicting cancer risk.
What Can We Do?
We provide methylation age and age acceleration measurements. Age prediction by our unique DNA methylation clock technology yields excellent prediction accuracy, and then age acceleration is estimated from the residuals of a linear regression of actual age against predicted age.
The goal of our service is to assess whether age acceleration in DNA methylation is associated with cancer risk, primarily through the results of statistical analysis of age acceleration data obtained from DNA samples at different stages of life.
We provide services for the study of the association between accelerated DNA methylation-based age measurement and increased risk of various cancers, including but not limited to the following research areas:
- Gastric cancer research
- Lung cancer research
- Kidney cancer research
- Breast cancer research
- Lymphoma research
- Rectal cancer research
CD BioSciences is committed to providing tailored research services to help clients overcome difficulties in age-accelerated methylation research and accelerate the development of cancer diagnosis and treatment. If you would like more information about our services, please feel free to visit and contact us to discuss how we can advance our aging research journey together.
- Joo J, et al. DNA methylation‐based biological aging and cancer risk and survival: Pooled analysis of seven prospective studies. Cancer Genetics and Epigenetics, 2017.
Our services are for research use only and not for any clinical use.
We are a comprehensive technology platform company integrating aging DNA methylation, telomere, transcriptome, proteome, and metabolome research.